Aranesp

Type: Product
Name: Aranesp
First reported Aug 15 2014 - Updated Aug 15 2014 - 2 reports

Amgen Inc. (AMGN) Rose To A New High Despite Disappointing Phase 3 Results

Amgen Inc. (AMGN: Quote) announced after the close Wednesday that its Phase 3 clinical trial of Kyprolis did not meet its primary endpoint of improving overall survival in patients with relapsed and advanced refractory multiple myeloma.Amgen also announced ... [Published RTTNews.com - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Amgen, Baxter, and Cubist Issue Recalls over Particulates

FDA has reported several pharmaceutical product recalls involving visible particulates.This week Baxter International Inc. voluntarily recalled two lots of DIANEAL Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL at the hospital/user ... [Published Pharmaceutical & Medical Packaging News - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 1 reports

Amgen (AMGN) gains despite drug test results

Amgen Inc. (NASDAQ: AMGN) shares took on 1.5% to $129.19. The biotechnology company announced disappointing results from a late-stage trial of its blood-cancer treatment, as well as a recall of its pre-filled syringes of its anemia drug Aranesp. Share ... [Published BayStreet.ca - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 2 reports

Amgen Recalls Lots of Aranesp

Amgen initiated a voluntary recall on June 26th for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and hospital pharmacies due to the potential presence of cellulose and/or polyester ... [Published Contract Pharma - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Most popular news headlines for Wednesday, August 13 2014

The most-clicked news item for Wednesday was “ BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt .”   This Fierce Pharma Marketing article details the reasons behind increased sales of the bloodthinner Eliquis, and how marketing actions ... [Published Cafepharma - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 2 reports

UPDATE: Berkshire Hathaway tops $200,000; Cisco drops on results

Gainers Berkshire Hathaway Inc.(BRKA): Class A shares of Warren Buffett's Berkshire Hathaway topped $200,000 for the first time, nearly eight years after first breaking through $100,000. Kohl's Corp. (KSS): The department-store retail chain's ... [Published Morningstar.com - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 2 reports

Amgen Blood Cancer Drug Fails Primary Endpoint In Late-Stage Study

Amgen Inc. (AMGN: Quote) and its subsidiary Onyx Pharmaceuticals Inc. Wednesday said the late-stage study of its blood cancer drug Kyprolis failed to meet its main goal of prolonging the overall survival of patients with relapsed multiple myeloma.The ... [Published RTTNews.com - Aug 13 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 3 reports

MARKET SNAPSHOT : U.S. Stocks Open Higher; Wal-Mart Cuts Outlook

By Anora Mahmudova and Carla Mozee, MarketWatchNEW YORK (MarketWatch) -- U.S. stocks opened slightly higher on Thursday, but gains were capped by a larger-than-expected jump in jobless claims and a cut in outlook by Wal-Mart, the world's largest retail ... [Published 4 Traders - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

U.S. stocks: Futures edge up with Wal-Mart results on deck

Futures for the Dow Jones Industrial Average (DJU4) rose 7 points to 16,626, while those for the S&P 500 index (SPU4)(SPU4) picked up 1.5 points, or 0.1%, to 1,946.50. Futures for the Nasdaq 100 index (NDU4) rose 4.5 points, or 0.1%, to 3,950.50. ... [Published Morningstar.com - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 3 reports

Amgen issues voluntary recall of Aranesp (500 mcg) prefilled syringes outside US

Amgen has initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose ... [Published PBR - News - Aug 14 2014]
First reported Aug 01 2014 - Updated Aug 02 2014 - 3 reports

Express Scripts drops Amgen anemia drugs from formulary | Reuters

6:58pm EDT (Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc.The company ... [Published DailyMe.Com - Aug 02 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 2 reports

Biosimilars of darbepoetin alfa

Related Biotechnology, Pharmaceutical and Healthcare NewsDarbepoetin alfa is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anaemia, commonly associated with chronic renal failure ... [Published BioPortfolio - Aug 01 2014]

Quotes

New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological drugs market is estimated at USD 1, 61,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach an estimated value of USD 2, 87,139.7 million in 2020."
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10...
No adverse events associated with these concerns were reported, it was stated in the news releases. FDA explains that "health implications related to particles, depending on the route of administration, would vary depending on the amount of particulate matter injected into the patient, the size of the particles, the patient's underlying medical condition, and the presence of a right-to-left cardiac shunt."
"Given our observation of an increased number of clearance zones at numerous stores, and rising amounts of excess seasonal goods on markdown as the second quarter moved along, Wal-Mart is at risk of missing second-quarter consensus earnings per share forecasts" wrote Brian Sozzi, chief equities strategist at Belus Capital Advisors, in a report earlier this week

More Content

All (77) | News (70) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Acute Management of Patients With Chronic Kidne... [Published U.S.Pharmacist - 3 hours ago]
Good News For Amgen As Parathyroid Drug AMG 416... [Published BioSpace - Aug 19 2014]
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
Manufacturing issues cause recalls for Amgen, B... [Published In-Pharmatechnologist - Aug 18 2014]
The Zacks Analyst Blog Highlights: Amgen, ANN, ... [Published Industrial Info Financials - Aug 15 2014]
Global Biological Drugs Market 2014 - 2020 - In... [Published Individual.com - Aug 15 2014]
Amgen Inc. (AMGN) Rose To A New High Despite Di... [Published RTTNews.com - Aug 15 2014]
Amgen, Baxter, and Cubist Issue Recalls over Pa... [Published Pharmaceutical & Medical Packaging News - Aug 15 2014]
Amgen hit as Kyprolis fails myeloma study [Published PMLive - Aug 15 2014]
Amgen Recalls Lots of Aranesp [Published Contract Pharma - Aug 14 2014]
Amgen's FOCUS Study on Multiple Myeloma Drug Ky... [Published Zacks.com - Aug 14 2014]
Most popular news headlines for Wednesday, Augu... [Published Cafepharma - Aug 14 2014]
Today's Market: Biotech And Technology Names Mo... [Published Seeking Alpha - Aug 14 2014]
Amgen recalls Aranesp syringes contaminated wit... [Published FiercePharmaManufacturing - Aug 14 2014]
UPDATE: Berkshire Hathaway tops $200,000; Cisco... [Published Morningstar.com - Aug 14 2014]
Amgen (AMGN) gains despite drug test results [Published BayStreet.ca - Aug 14 2014]
UPDATE: Plug Power rallies, GM drops on sell ra... [Published Morningstar.com - Aug 14 2014]
MARKET SNAPSHOT : U.S. Stocks Open Higher; Wal-... [Published 4 Traders - Aug 14 2014]
Lackluster Sentiment May Prevail Amid Weak Data... [Published RTTNews.com - Aug 14 2014]
MARKET SNAPSHOT: U.S. Stocks: Futures Turn Flat... [Published Nasdaq - Aug 14 2014]
MARKET SNAPSHOT: U.S. Stocks: Futures Stay Up A... [Published 4 Traders - Aug 14 2014]
Amgen Expected To Fall As Cancer Drug Kyprolis ... [Published Bidness Etc - Aug 14 2014]
U.S. stocks: Futures edge up with Wal-Mart resu... [Published Morningstar.com - Aug 14 2014]
Amgen issues voluntary recall of Aranesp (500 m... [Published PBR - News - Aug 14 2014]
Amgen Announces Trial Setback, Recall [Published Los Angeles Business Journal - Aug 14 2014]
Amgen recalls syringes of anemia drug Aranesp [Published DailyMe.Com - Aug 14 2014]
Amgen Blood Cancer Drug Fails Primary Endpoint ... [Published RTTNews.com - Aug 13 2014]
UPDATE 1-Amgen drug fails to improve survival i... [Published CNBC - Aug 13 2014]
Amgen recalls certain lots of Aranesp [Published Seeking Alpha - Aug 13 2014]
Wal-Mart, Cisco are stocks to watch Thursday [Published Morningstar.com - Aug 13 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological ...
Amgen issues voluntary recall of Aranesp (500 m... [Published PBR - News - Aug 14 2014]
Amgen has initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose ...
Amgen Drops in After Hours on Failed Trial, Recall [Published BARRONS.com Stocks To Watch Today - Aug 13 2014]
Shares of Amgen (AMGN) are falling in after-hours trading after the biotech giant announced that a drug trial had failed and it had to recall one of its drugs due to visible particulates. Steve Remich Amgen said that it had recalled prefilled syringes ...
Amgen Issues Voluntary Recall of Aranesp® (darb... [Published PR Newswire: Consumer Products & Retail - Aug 13 2014]
THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a ...
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published Marketwire - Breaking News Releases - Jun 18 2014]
HYDERABAD, INDIA--(Marketwired - Jun 18, 2014) - The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.